Login
Companies $DYN
$16.75 -$0.41 (2.39%) Live
Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

dyne-tx.com

What Do They Do?

Develops treatments for genetically driven neuromuscular diseases, including muscular dystrophies and Pompe disease.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −79% (Loss)
vs −$108M in Q3 FY2025
  • Jul 29, 2026 FDA accepts z-rostudirsen application for priority review The FDA set a January 21, 2027 target action date; the company also reported FDA clearance for DYNE-302.
  • Jul 22, 2026 Dyne priced a public stock offering The offering is expected to generate $375,150,000 in gross proceeds before costs and extend its cash runway into the second quarter of 2028.

Pompe and enzyme medicines The older report described programs for myotonic dystrophy, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy, using oligonucleotide payloads; the latest report adds Pompe disease and an enzyme payload.

Broader delivery target The older report described FORCE as delivering treatments to muscle; the latest also describes delivery to the central nervous system.

Who Do They Compete With?

Competes with PTC Therapeutics, Catalyst Pharmaceuticals, ITF Therapeutics, Sarepta Therapeutics, Nippon Shinyaku, Wave Life Sciences, Entrada Therapeutics, BioMarin Pharmaceuticals, SQY Therapeutics, NS Pharma, Avidity, Solid Biosciences, REGENXBIO, Genethon, Insmed, Vertex, AMO Pharma, Harmony Biosciences, Pepgen, and Arrowhead Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support